Group 1: Industry Insights - The article discusses various upcoming webinars focusing on different industries, including transportation, machinery, AI, finance, automotive, and pharmaceuticals [1][32]. - Each session is led by a specialized analyst, indicating a structured approach to industry analysis and insights [1][32]. Group 2: Webinar Schedule - The first session on March 29 focuses on the analysis of Zhongyuan Expressway, led by Cheng Zhifeng, a transportation analyst [1][32]. - The second session on March 30 will update on the machinery industry, presented by Cui Wenjuan, the chief machinery analyst [1][32]. - Another session on March 30 will delve into AI video developments, highlighting model acceleration and the value of tools and IP, led by Zheng Lei and Li Linhui [1][32]. - On April 1, there will be a review and update of the industry allocation model, presented by Liu Xiaofeng, the chief quantitative analyst [1][32]. - The April 2 session will revisit Elon Musk's V3 moment, focusing on Optimus V3 and Starship V3, led by Liu Hongchen, the chief automotive analyst [1][32]. - The final session on April 3 will cover the small nucleic acid industry, specifically the path to drug development, presented by Zhou Yu and Rong Xiaojie, both pharmaceutical analysts [1][32].

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their applications from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways of Small Nucleic Acid Drug Development - ASO and siRNA represent two distinct technological pathways, with ASO focusing on RNA degradation and splicing regulation, while siRNA employs the RISC mechanism for mRNA degradation [12][26] Chemical Modifications and Stability - The report outlines four generations of chemical modifications that enhance the stability and specificity of ASO, which are crucial for their therapeutic efficacy [32][36] Delivery Breakthroughs - The report identifies the challenges of delivering small nucleic acids across cellular barriers, emphasizing the need for effective delivery systems to overcome these obstacles [40][43] Safety Optimization - Innovations in safety management, such as the development of antidotes for siRNA and toxicity control for ASO, are essential for supporting long-term use and chronic disease management [3][62] Commercialization and Boundary Expansion - The industry is moving from liver-targeted therapies to exploring delivery strategies for other tissues, with companies like Alnylam aiming for multi-organ delivery by 2030 [60][61]

Investment Rating - The report does not explicitly state an investment rating for the small nucleic acid industry Core Insights - Small nucleic acid drugs have transitioned from technical validation to commercial realization, with projected sales of approximately $3.1 billion for ASO and $4.2 billion for siRNA by 2025 [3] - The development paths of ASO and siRNA are shaped by their mechanistic differences, with ASO utilizing a single-strand structure for direct delivery into target cells, while siRNA relies on carrier systems for effective delivery due to its larger size and strong negative charge [3] - Continuous evolution in chemical modifications and delivery platforms has improved the stability, targeting, safety, and convenience of small nucleic acid drugs, expanding their application from rare diseases to chronic conditions [3] - Current advancements in liver-targeting technologies are paving the way for the next phase of delivery to extrahepatic tissues, with future valuations of small nucleic acid companies focusing on platform capabilities and expansion into chronic disease treatments [3] Summary by Sections Small Nucleic Acids Unlock Gene Expression Regulation - Small nucleic acid drugs can target previously undruggable proteins by intervening at the gene expression level, significantly broadening the potential therapeutic targets [9][11] Pathways to Small Nucleic Acid Drug Development - The report outlines the dual pathways of ASO and siRNA, highlighting their distinct mechanisms and therapeutic applications [12][30] Mechanistic Differences: ASO vs. siRNA - ASO employs RNase H-mediated degradation and splicing regulation to inhibit protein expression, while siRNA utilizes the RISC mechanism for mRNA degradation [20][26] Chemical Modifications and Stability - The report details the evolution of chemical modifications across four generations, enhancing the stability and specificity of ASO and siRNA [32][36] Delivery Breakthroughs - The challenges of delivering small nucleic acids across cellular barriers are discussed, emphasizing the need for effective delivery systems [40][44] Safety Optimization - Innovations in toxicity management for ASO and siRNA are crucial for supporting long-term use and chronic disease management [62][64] Commercialization and Boundary Expansion - The report emphasizes the transition from liver-targeted therapies to exploring delivery strategies for other tissues, indicating a strategic shift in the industry [60][61]